The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.
 
Efrat Dotan
Consulting or Advisory Role - Agenus; Amgen; G1 Therapeutics; Incyte; Olympus; Taiho Pharmaceutical
Research Funding - Dragonfly Therapeutics (Inst); Gilead Sciences (Inst); Ipsen (Inst); Kinnate Biopharma (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lutris (Inst); NGM Biopharmaceuticals (Inst); Relay Therapeutics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Olympus
 
Paul J. Catalano
Research Funding - Astellas Pharma (Inst); Regeneron (Inst)
 
Leon Lenchik
No Relationships to Disclose
 
Robert Boutin
Research Funding - GE Healthcare (Inst)
 
Xin Yao
Employment - Cleveland clinic Martin North (I)
Honoraria - OMNI; Research to Practice; Targeted Oncology
 
James Ohr
No Relationships to Disclose
 
Kian-Huat Lim
Honoraria - CURIS
Patents, Royalties, Other Intellectual Property - Hold patent for targeting MK2 as a therapeutic strategy in pancreatic cancer.
 
Namrata Vijayvergia
Honoraria - Guidepoint Global
Consulting or Advisory Role - Exelixis; ITM Isotope Technologies Munich; RayzeBio; Taiho Oncology
Research Funding - Bristol-Myers Squibb/Medarex (Inst); Oryzon Genomics (Inst); Puma Biotechnology (Inst); Zymeworks (Inst)
 
Sreenivasa R Chandana
Speakers' Bureau - Natera
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Cardiff Oncology (Inst); Dicephera Pharmaceuticals, Inc. (Inst); Elevation Oncology (Inst); Exact Sciences (Inst); Genentech/Roche (Inst); IDEAYA Biosciences (Inst); IgM Biosciences (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novocure (Inst); Pfizer (Inst); Qualigen Therapeutics (Inst); Zymeworks (Inst)
 
Aparna Kalyan
Honoraria - Samumed
Consulting or Advisory Role - AstraZeneca; Boston Scientific; BTG; Elevar Therapeutics; Exelixis; Genentech; Incyte
Speakers' Bureau - AstraZeneca; Boston Scientific; Exelixis; Genentech/Roche
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
 
Richard Francis Dunne
Consulting or Advisory Role - Exelixis; Helsinn Therapeutics; Merck; Toray Industries Inc.
 
David Bing Zhen
Consulting or Advisory Role - Cornerstone Pharmaceuticals; Ipsen; Jazz Pharmaceuticals
Research Funding - A2 Biotherapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Cornerstone Pharmaceuticals (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Genentech (Inst); Legend Biotech (Inst); Lilly (Inst); Merck (Inst); Seagen (Inst); TME Pharma (Inst)
 
Daneng Li
Consulting or Advisory Role - Abbvie; AstraZeneca; Delcath Systems; Eisai; Exelixis; Genentech; Merck; Sumitomo Pharma Oncology; Tersera; TransThera Biosciences; TriSalus Life Sciences
Speakers' Bureau - Eisai; Exelixis; Ipsen; SERVIER; Tersera
Research Funding - AstraZeneca (Inst)
 
Melissa A. Simon
No Relationships to Disclose
 
Jordan Berlin
Consulting or Advisory Role - Bayer Health; Bexion; BioSapien; Bristol-Myers Squibb/Celgene; insmed; ipsen; Mekanistic Therapeutics; Merck; Merck KGaA; Merus; Mirati Therapeutics; Oxford BioTherapeutics
Research Funding - 23andMe (Inst); Abbvie (Inst); Astellas Pharma (Inst); Atreca (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Bristol-Myers Squibb/Celgene (Inst); Day One Biopharmaceuticals (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); hibercell (Inst); I-MAB (Inst); Incendia Pharmaceuticals AB (Inst); Incyte (Inst); Lilly (Inst); ribosciences (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Totus Medicines (Inst); Tyra Biosciences (Inst); Volastra Therapeutics (Inst)
Other Relationship - AstraZeneca; Boehringer Ingelheim; novocure
 
Lynne I. Wagner
Consulting or Advisory Role - Celgene
Travel, Accommodations, Expenses - Celgene
 
Peter J. O'Dwyer
Research Funding - Amgen (Inst); Array BioPharma (Inst); BBI Healthcare (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Lilly/ImClone (Inst); Minneamrita Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); syndax (Inst); Taiho Pharmaceutical (Inst)